Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination

AIDS

Volumn 21, Issue 1, 2007, Pages 106-108

  Duval, Xavier ^a,b   Peytavin, Gilles ^a   Breton, Guillaume ^a   Ecobichon, Jean Luc ^a   Descamps, Diane ^a,b   Thabut, Gabriel ^a   Leport, Catherine ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; RITONAVIR;

ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; HAIR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CONFIDENCE INTERVALS; DRUG COMBINATIONS; HAIR; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; ODDS RATIO; RITONAVIR;

EID: 33845479475     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280118486     Document Type: Article

References (11)

1. Ghosn J, Lamotte C, Ait-Mohand H, Wirden M, Agher R, Schneider L, et al. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003; 17:209-214.
2. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679-686.
3. Mannheimer S, Morse E, Matts J, Andrews L, Miller C, Schmetter B, et al. Adherence strategies using a medication manager and an electronic medication reminder system for HIV Infected patients receiving HAART. In: XVth International AIDS Conference. Bangkok, Thailand 2004 [Abstract LbOrB15].
4. Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16 (Suppl. 1):S5-S37.
5. Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17:1157-1165.
6. Burger DM, Hoetelmans RM, Hugen PW, Mulder JW, Meenhorst PL, Koopmans PP, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998; 3:215-220.
7. Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J Jr, Gallant JE, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42:1189-1196.
8. Duval X, Mentre F, Lamotte C, Chene G, Spire B, Dellamonica P, et al. Indinavir plasma concentration and adherence score are codeterminant of early virological response in HIV-infected patients of the APROCO cohort. Ther Drug Monit 2005; 27:63-70.
9. Servais J, Peytavin G, Arendt V, Staub T, Schneider F, Hemmer R, et al. Indinavir hair concentration in highly active antiretroviral therapy- treated patients: association with viral load and drug resistance. AIDS 2001; 15:941-943.
10. Bernard L, Vuagnat A, Peytavin G, Hallouin MC, Bouhour D, Nguyen TH, et al. Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy. Ann Intern Med 2002; 137:656-659.
11. Woolf E, Au T, Haddix H, Matuszewski B. Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching. J Chromatogr A 1995; 692:45-52.